A Prospective Observational Study Of Erivedge Treatment, Effectiveness, and Safety Outcomes In Patients With Advanced Basal Cell Carcinoma

Trial Profile

A Prospective Observational Study Of Erivedge Treatment, Effectiveness, and Safety Outcomes In Patients With Advanced Basal Cell Carcinoma

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Jul 2016

At a glance

  • Drugs Vismodegib (Primary)
  • Indications Basal cell cancer; Basal cell nevus syndrome
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 01 Jul 2016 Planned number of patients changed from 50 to 40.
    • 01 Jul 2016 Planned End Date changed from 1 Mar 2020 to 1 Dec 2019.
    • 01 Jul 2016 Planned primary completion date changed from 1 Mar 2020 to 1 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top